Long term thérapy for PE of VTE. C Becattini for the WARFASA study Randomisée TVP sans cause retrouvée De 6 à 18 mois de TTT.

Fibrillation atriale: avis d’expert sur les antithrombotiques
Apixaban versus warfarin in patients with atrial fibrillation
RE-LY Randomization Evaluation of Long-Term Anticoagulation Therapy Connolly S.J et al. N Engl J Med 2009 ; 361.
ROCKET AF Rivaroxaban Once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in Atrial.
Critère principal : décès CV, IDM ou AVC n = Médiane de suivi 33 mois
AVERROES Apixaban versus acetylsalicylic acid (ASA) to reduce the risk of stroke Connolly S et al. ESC 2010.
ROCKET AF Rivaroxaban versus warfarine dans la fibrillation atriale non valvulaire Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. Patel.
CRASH-2 Effets de l’acide tranexamique sur la mortalité, les événements cardiovasculaires et la transfusion sanguine chez les patients traumatisés ayant.
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack CHANCE Wang Y et al. N Engl J Med 2013 ;369:11-19.
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban once daily, oral,
PROTECT AF Fermeture percutanée de l’auricule gauche versus warfarine en prévention des AVC chez des patients en fibrillation auriculaire : étude randomisée.
Quantification du biais d’estimation Par méta-analyse exemple avec les nouveaux anticoagulants oraux dans la fibrillation atriale Jean-Christophe Lega.
Cerebrovascular events in patients with atrial fibrillation randomized to edoxaban versus warfarin : effective anticoagulation with factor Xa next.
FREEDOM Strategies for Multivessel Revascularization in Patients with Diabetes N Engl J Med 2012 DOI : /NEJMoa Farkouh ME et al. AHA 2012.
RE-LY Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial.
REGISTRE IMPROVE Prophylaxie de la maladie thrombo-embolique veineuse (MTEV) chez des patients hospitalisés pour une pathologie aiguë en service de médecine.
FAME 2 Fractional Flow Reserve-Guided PCI versus Medical Therapy in Stable Coronary Disease De Bruyne B et al. ESC 2012.
Aspirin in Patients Undergoing Non Cardiac Surgery POISE 2 Devereaux PJ et al. NEJM 2014;370:
ARISTOTLE Apixaban versus warfarine dans la fibrillation atriale
MTEV ET CANCER EVOLUTIF Thrombose veineuse chez les patients atteints de cancer évolutif Seddighzadeh A et al. Thromb Haemost 2007; 98: Venous.
ACTIVE A Prévention des événements de la fibrillation auriculaire par le clopidogrel Effect of Clopidogrel added to Aspirin in patients with Atrial Fibrillation.
JPPP Low-dose aspirin for primary prevention of cardiovascular events in elderly patients with multiple atherosclerotic risk factors. A randomized control.
Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention : systematic review and meta-analysis. Enoxaparine.
Explore the efficacy and safety of once-daily oral rivaroxaban for the prevention of cardiovascular events in subjects with non-valvular atrial fibrillation.
Prasugrel vs Clopidogrel for Acute Coronary Syndromes without Revascularization TRILOGY ACS Roe MT et al. N Engl J Med 2012 ; 367:
Edoxaban versus warfarin in patients with atrial fibrillation. ENGAGE-AF TIMI 48 Giugliano RP, et al. N Engl J Med 2013 ; 369 :
ASPIRE Low-dose Aspirin for Preventing Recurrent Venous Thromboembolism N Engl J Med 2012 DOI : /NEJMoa Brighton TA et al. AHA 2012.
La Lettre du Cancérologue Critères d’efficacité Co-primaires : SG SSP radiographique Secondaires : temps jusqu’à Progression de la douleur Progression.
Syndrome Cardiorénal Prédire la dégradation de la fonction rénale par le dosage de biomarqueurs de congestion cardiaque et dʼagression rénale aiguë MEMOIRE.
Rome – ESC 2016 Marie Viala, CHU Montpellier-Nîmes TDLB
RE-MODEL Study Essai clinique randomisé comparant
WOEST First randomised trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting. Dewilde.
ARV-trial.com Switch pour MVC MARCH Study 1.
X-VERT Explore the efficacy and safety of once-daily oral rivaroxaban for the prevention of cardiovascular events in subjects with non-valvular atrial.
TRAITEMENT ANTI-THROMBOTIQUE POST-TAVI
NACO AOD ACD.
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
THE CANAL COHORT STUDY Facteurs de risque de développement d’inhibiteur liés au traitement chez des patients naïfs atteints d’hémophilie A. Treatment-related.
Moderate Pulmonary Embolism treated with thrombolysis
FVIIIr Pégylé Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstitued with pegylated liposomes Spira J and.
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
ADVANCE-3 Apixaban versus enoxaparin for thromboprophylaxis after hip replacement Lassen MR et al NEJM 2010; 363 :
PROTECT Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation : a randomised.
ATLAS ACS 2 – TIMI 51 Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome Gibson CM.
1–Thrombolysis in myocardial infarction
IST-3 The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6h of acute ischaemic stroke (the third international.
CALISTO Fondaparinux pour le traitement
Surveillance AVK Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios.
RE-MEDY & RE-SONATE Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism. Utilisation prolongée du dabigatran, de la warfarine.
3 Karine Gourd R1 Étienne Béliveau Tse R1 UMF de Verdun
WOEST First randomised trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting. Dewilde.
Pr L CHRISTIAENS Actualités ESC 2017 Pr L CHRISTIAENS
ACCOAST Pretreatment with prasugrel in non-ST elevation acute coronary syndromes ESC 2013 Montalescot G, et al. N Engl J Med 2013.
Dabigatran versus warfarin in patients with atrial fibrillation.
AMADEUS Comparaison de l’idraparinux avec les AVK en prévention des accidents thrombo-emboliques de la fibrillation auriculaire : étude randomisée, ouverte,
HOKUSAI-VTE Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism ESC 2013 Büller HR et al. N Engl J Med 2013 ; 369 :
Effets cardiovasculaires du traitement intensif de l’hypertension chez les adultes et personnes âgées Par Mohamed Al-Azzawi et Christopher Lam UMF St-Hubert.
CMD non-ischémique & DAI ESC congress 2016
Platelet inhibition and patient outcomes
Strategies for Multivessel Revascularization in Patients with Diabetes
Traitement en double-aveugle Puissance pour supériorité
382 patients randomisés 349 patients en suivi post-traitement
Barrière hémato encéphalique
TRA 2° P Vorapaxar in the secondary prevention in atherothrombotic events Morrow DA et al. N Engl J Med 2012 ; 366 : Morrow DA et al. ACC 2012.
180 mg 1/j précédé par 7 jours à 90 mg 1/j (bras A)
Étude ASCEND : AAS 100 mg/jour chez diabétiques sans maladie cardio-vasculaire à l’inclusion (1) Réalisée au Royaume-Uni 63 ans d’âge moyen, 63.
Étude VERDICT : approche invasive précoce dans les NSTEMI (1)
Host-ASSURE Adjunctive Cilostazol vs double dose clopidogrel after PCI with drug eluting stent Hyo-Soo K et al. ACC 2012.
TRILOGY ACS Prasugrel vs Clopidogrel for Acute Coronary Syndromes Patients managed without Revascularization. Ohman M, et al. ESC 2012.